Abstract
To evaluate the efficacy of nivolumab and comparison with dacarbazine (DTIC) on peritoneal carcinomatosis of malignant melanoma in mouse model. Mouse skin melanoma cells was injected under the capsule of the peritoneal surface in the left side of the abdomen. On postoperative day ten, mouses randomised into three groups. Group 1: Control, Group 2: HIPEC (Hyperthermic intraperitoneal chemotherapy) with DTIC and Group 3: HIPEC with Nivolumab. After the sacrification on postoperative day fifteen, peritoneum evaluated macroscopically and histopathologically by using peritoneal regression grading score (PRGS). In the 15th day exploration, all animals developed extensive intraperitoneal tumor growth in Group 1. In Group 2 and Group 3 median tumor size was 0.7±0.3cm and 0.3±0.2cm respectively (p: 0.023). Peritoneal carcinomatosis index (PCI) were significantly lower in Group 3 than other groups (p: 0.019). The lowest total tumor nodules in group 3 was 4 ± 2. The PGRS score was found significantly lower in Group 3 than other groups (p: 0.03). Lymphocytic response rate was found higher in the Group 3. It has been found that nivolumab significantly better than DTIC on peritoneal metastases of malign melanoma in mouse models. Nivolumab treatment gives promising results with pathological evidence in the treatment of metastatic disease of malignant melanoma.
Highlights
Malignant melanoma(MM) is a malignant neoplasm that arises from melanocyte and typically occur in the skin but may rarely occur in other locations and can give rise to primary melanoma in unexpected locations as peritoneum
Two mice died in each Group 2 and Group 3 and 1 mouse died in Group 1 during the follow-up
The PGRS score was found to be lower in the Nivolumab group than in the DTIC and control groups (p: 0.03)
Summary
Malignant melanoma(MM) is a malignant neoplasm that arises from melanocyte and typically occur in the skin but may rarely occur in other locations and can give rise to primary melanoma in unexpected locations as peritoneum. It metastasizes to all organs of the body and often demonstrates unpredictable metastatic behavior. In 2017 National Comprehensive Cancer Network (NCCN) guideline, Nivolumab is used as a first line and second line treatment for inoperable or metastatic melanoma[4,5]. The effects of DTIC versus Nivolumab treatment on melanoma cells were compared in this study,
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
